Ifosfamide: Clinical Trials

94 trials of Ifosfamide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

48 completed, 18 unknown, 9 active not recruiting, 8 recruiting. 94 Phase 3, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 394Completed 48, Unknown 18, Active not recruiting 9, Recruiting 8, Terminated 7, Not yet recruiting 2, Withdrawn 2
Phase 27Completed 2, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1

Follow Ifosfamide: new trials by email Literature Review of Ifosfamide trials Research Report on Ifosfamide

Trials (filtered) newest first · largest first

All 94 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall
Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma
Phase 3Not yet recruitingOhio State University Comprehensive Cancer Center2282026-12-012026-09-16
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3Not yet recruitingNational Cancer Institute (NCI)2712026-10-302026-08-19
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma
Phase 2 / Phase 3TerminatedChildren's Oncology Group22025-11-102026-10-05
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Biospecimen Collection, Bone Scan, Computed Tomography - Pleuropulmonary Blastoma
Phase 3RecruitingChildren's Oncology Group1102025-03-212026-08-25
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 3RecruitingBeBetter Med Inc4162025-01-062026-08-19
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma
Phase 2 / Phase 3RecruitingUniversity of Birmingham2102024-05-022026-02-20
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Odronextamab, Ifosfamide, Carboplatin - B-Cell Non-Hodgkin Lymphoma (B-NHL)
Phase 3Active not recruitingRegeneron Pharmaceuticals2162024-02-152026-05-11
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
Autologous Hematopoietic Stem Cell Transplantation, Bendamustine, Brentuximab Vedotin - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Phase 3WithdrawnNational Cancer Institute (NCI)2023-08-102024-03-20
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide - T-cell Lymphoblastic Lymphoma
Phase 3RecruitingChildren's Cancer Group, China2002023-02-062026-03-19
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
Polatuzumab Vedotin, Mabthera, Ifosfamide - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 3CompletedGWT-TUD GmbH3062021-04-302026-06-10
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Vincristine, Carboplatin, Etoposide - High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
Phase 3RecruitingGustave Roussy, Cancer Campus, Grand Paris8002019-11-052025-06-26
A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy
Sintilimab, Carboplatin, Etoposide - Classic Hodgkin's Lymphoma
Phase 3UnknownInnovent Biologics (Suzhou) Co. Ltd.2402019-10-212022-09-14
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Cyclophosphamide, Cytarabine, Dexamethasone - Lymphoblastic Lymphoma, Childhood
Phase 3RecruitingUniversity Hospital Muenster6832019-08-232026-05-06
Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator - Non-metastatic Soft-tissue Sarcoma, Resectable
Phase 3RecruitingInstitut BergoniƩ3512019-02-142025-10-02
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Blinatumomab, Bortezomib, Cyclophosphamide - Acute Lymphoblastic Leukemia, Pediatric
Phase 3RecruitingMartin Schrappe50002018-07-152025-04-06
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Phase 3Active not recruitingChildren's Oncology Group3522017-08-082026-10-05
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
Rituximab window, Additional doses of Rituximab, Cyclophosphamide - Mature B-cell Non-Hodgkin Lymphoma
Phase 3Active not recruitingUniversity Hospital Muenster6502017-08-032026-04-30
SIMPLE Chemotherapy for NK Lymphoma/Leukaemia
Cisplatin, Gemcitabine, Etoposide (VP-16) - Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin T-cell Lymphoma
Phase 3UnknownThe University of Hong Kong682017-07-012018-08-14
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
ILND - Inguinal Lymph Node Dissection, Paclitaxel, Ifosfamide - Squamous Cell Carcinoma of the Penis, Usual Type
Phase 3Active not recruitingInstitute of Cancer Research, United Kingdom2002017-05-122026-08-31
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Ibrutinib, Rituximab, Ifosfamide - Lymphoma, Non-Hodgkin
Phase 3TerminatedJanssen Research & Development, LLC722016-07-012022-12-02

Showing 20 of 94. Sign in to see all of them.

Conditions studied

Sarcoma (23)  ·  Fibrosarcoma (9)  ·  Liposarcoma (9)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (9)  ·  Hemangiosarcoma (8)  ·  Lymphoma (8)  ·  Histiocytoma, Malignant Fibrous (7)  ·  Leiomyosarcoma (7)  ·  Lymphoma, Large B-Cell, Diffuse (7)  ·  Neurofibrosarcoma (7)  ·  Sarcoma, Synovial (7)  ·  Hemangiopericytoma, Malignant (6)  ·  Leukemia (6)  ·  Malignant mesenchymal tumor (6)  ·  Rhabdomyosarcoma (6)

Sponsors

Children's Oncology Group (14)  ·  National Cancer Institute (NCI) (9)  ·  European Organisation for Research and Treatment of Cancer - EORTC (7)  ·  Gustave Roussy, Cancer Campus, Grand Paris (4)  ·  UNICANCER (3)  ·  University Hospital Muenster (3)  ·  Alliance for Clinical Trials in Oncology (2)  ·  Children's Cancer Group, China (2)  ·  Children's Cancer and Leukaemia Group (2)  ·  European Lung Cancer Working Party (2)  ·  European Paediatric Soft Tissue Sarcoma Study Group (2)  ·  German Society for Pediatric Oncology and Hematology GPOH gGmbH (2)  ·  Gynecologic Oncology Group (2)  ·  Italian Sarcoma Group (2)  ·  M.D. Anderson Cancer Center (2)

Countries

United States (37)  ·  United Kingdom (25)  ·  Germany (24)  ·  Switzerland (23)  ·  Australia (22)  ·  France (22)  ·  Canada (21)  ·  Spain (19)  ·  Belgium (18)  ·  Netherlands (18)  ·  Austria (16)  ·  Italy (13)  ·  Puerto Rico (13)  ·  Denmark (12)  ·  Sweden (12)

Top investigators

Alan W. Craft, MD (2)  ·  Birgit Burkhardt, Prof. Dr. Dr. (2)  ·  Frank Berthold, MD (2)  ·  Heribert F. Juergens, MD (2)  ·  Higinia R. Cardenes, MD, PhD (2)  ·  Ian R. Judson, MA, MD, FRCP (2)  ·  Jean-Paul Sculier, MD, PhD (2)  ·  Laurence Brugieres, MD (2)  ·  A.N. Van Geel, MD (1)  ·  Aaron H. Wolfson, MD (1)  ·  Aaron R Weiss (1)  ·  Adrian Hodson (1)  ·  Amos Burke (1)  ·  Andrea Biondi (1)  ·  Andrea Ferrari, MD (1)

Results publications

PMID 33242441, PMID 16421426, PMID 19433688, PMID 20154213, PMID 21719599, PMID 24344215, PMID 26888258, PMID 26913693, PMID 29148893, PMID 31401903, PMID 31601692, PMID 33152759, PMID 35271306, PMID 37021527, PMID 37505794, PMID 10499612, PMID 10627444, PMID 10882162, PMID 11426549, PMID 11464889, PMID 12101494, PMID 12165894, PMID 12880954, PMID 12932669, PMID 16129365, PMID 16157935, PMID 16293867, PMID 16572419, PMID 17003366, PMID 17290061, PMID 17544497, PMID 17634494, PMID 17761975, PMID 17822748, PMID 17971487, PMID 18239620, PMID 18780832, PMID 18802150, PMID 19546402, PMID 19760772, PMID 20108339, PMID 20308673, PMID 20434400, PMID 20547982, PMID 20660832, PMID 20679620, PMID 20694800, PMID 20944675, PMID 21059637, PMID 21280197

NIH funding

U10CA098543 (10), U10CA180886 (8), 2017 (2), U10CA180821 (2), U10CA180830 (2), 2004 (1), 2005 (1), 2014 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), P30CA013330 (1), P30CA016672 (1), U10CA027469 (1)